Vinícius de Camargo Callefi

Mr. Vinícius de Camargo Callefi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2025 in JMIR Preprints
Verified
Preprint
Open access
NANelio Cezar De Aquino
Nelio Cezar De Aquino
CRCadiele Oliana Reichert
Cadiele Oliana Reichert
VCVinícius de Camargo Callefi
Vinícius de Camargo Callefi
VRVictor Santos Duarte Ramos
Victor Santos Duarte Ramos
YSYael Sznajder
Yael Sznajder
JPJuliana Pereira
Juliana Pereira
BACKGROUND Real-World Evidence (RWE) is increasingly used for clinical and regulatory decisions. However, the quality of real-world data (RWD) (e.g., electronic health records, claims, registries) remains a challenge to credible evidence generation. OBJECTIVE The objective of this Scoping Review is to synthesize the current literature on Real-World Evidence (RWE) Data Quality (DQ), specifically focusing on identifying and mapping the scope and nature of terminological inconsistency in DQ dimensions and assessment methods, and to analyze how these challenges impact the operationalization of the 'Fit-for-Purpose' (FFP) principle in RWE data assessment. METHODS This scoping review involved a systematic search of three databases (PubMed, Web of Science, and Scopus) for publications dated between January 2013 and July 2, 2025. The search targeted documents addressing frameworks, dimensions, and assessment methods related to data quality for RWE. To ensure comprehensive coverage, the primary search was supplemented using backward citation tracking (snowballing) to identify foundational literature. Data extraction focused on quality dimensions, their context of use, and their practical application. RESULTS Ninety-one eligible documents were included, concentrated in North America and Europe. Hybrid publications (academia-industry-government collaborations) constituted the majority (54.9%). A high prevalence (43%) of reported financial conflicts of interest (COI) was identified. The most cited RWD sources were EHRs, claims, and registries. Despite lacking a standardized lexicon, Completeness was the most reported Data Quality Dimension (DQD) (78 documents), followed by Accuracy (66), Consistency (47), Compliance (43), and Reliability (42). Validity and Currentness/Timeliness (41 each), Plausibility (39), and Relevance (37) were also prominent. "Fit For Purpose" (FFP) was central (57% of documents), defined as a context-dependent judgment of data suitability for a specific secondary application. While 41% of publications cited no specific framework, the Kahn et al. harmonized framework and the U.S. FDA’s RWE Program Framework were the most prominent. CONCLUSIONS This review characterizes the RWE field as a collaborative yet fragmented ecosystem, concentrated in North America/Europe and marked by prevalent financial COIs. RWE credibility is fundamentally undermined by "terminological chaos": the lack of a standardized data quality lexicon. Key dimensions are used without consensus definitions, hindering reproducibility. This ambiguity makes the field's core FFP principle operationally unstable, as its components (e.g., reliability, relevance) also lack consensus. This subjectivity is high-risk given the prevalent COIs. A viable path forward requires moving beyond isolated frameworks toward an integrated, multi-stage solution: adopting foundational standards (e.g., ISO/IEC 25012, DAMA-DMBOK) for Upstream integrity, using Common Data Models (e.g., OMOP) for Midstream interoperability, and mandating Downstream transparency through protocol pre-registration and FAIR-aligned quality reports. CLINICALTRIAL The study protocol was registered with the Open Science Framework-OSF database under DOI 10.17605/OSF.IO/V5M86

22 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Davi Ferreira JofreDavi Ferreira Jofre
Davi Ferreira Jofre
GGGiulia Sales Guimarães
Giulia Sales Guimarães
ARAna Beatriz Rocha
Ana Beatriz Rocha
JCJéssica Bilar Cavalcanti
Jéssica Bilar Cavalcanti
PBPriscila Barros
Priscila Barros
HCHebert Fabricio Culler
Hebert Fabricio Culler
Background/Objectives: T-cell receptor gamma (TCRγ) clonality testing by multiplex polymerase chain reaction (PCR) is an important ancillary method in the diagnostic evaluation of T-cell lymphoproliferative disorders. Interpretation is particularly challenging in HTLV-1 infection, in which persistent antigenic stimulation may produce clonal or oligoclonal T-cell expansions overlapping with non-neoplastic patterns. This study aimed to assess the diagnostic performance and interpretative contribution of two EuroClonality/BIOMED-2 assays (TCRγ-A and TCRγ-B), considered complementary components of the same analytical panel, and a single-tube multiplex PCR assay (TCRγ-O), and to develop an integrated workflow for TCRγ clonality interpretation. Methods: A total of 107 peripheral blood samples were analyzed, including 19 healthy donors, 75 HTLV-1 carriers, and 13 patients with adult T-cell leukemia/lymphoma (ATLL). TCRγ clonality was evaluated using three multiplex PCR assays followed by capillary electrophoresis. Profiles were classified as polyclonal, oligoclonal, or monoclonal. Diagnostic performance analysis was performed using healthy donors as the reference negative group and ATLL patients as the reference positive group. Results: The combined EuroClonality approach (TCRγ-A+B) showed the highest sensitivity (100%), whereas TCRγ-O showed the highest specificity (94.7%). TCRγ-A and TCRγ-B each showed a sensitivity of 76.9%, with specificities of 84.2% and 78.9%, respectively. Classification was highly concordant in healthy donors and ATLL patients employing both assays. However, among HTLV-1 carriers, classification varied across the assays. The integrated workflow was associated with a significant change in the distribution of molecular classification patterns in the HTLV-1 group compared with EuroClonality-based interpretation alone. (Stuart–Maxwell, p < 0.001). Conclusions: The EuroClonality/BIOMED-2 strategy provided greater sensitivity, whereas TCRγ-O showed greater specificity. Their integration supported a complementary and hierarchical approach to TCRγ clonality assessment, particularly in HTLV-1 infection. These findings support an exploratory integrated framework for TCRγ clonality interpretation in HTLV-1 infection and ATLL, requiring validation in larger independent cohorts.